Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT06327633 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effects of Olfactory Training on the Brain Function in T2DM Patients With Mild Cognitive Impairment

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This is a pilot, prospective, randomized, open label, parallel, 4-month study to explore and evaluate the therapeutic effects of olfactory training on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with mild cognitive impairment (MCI).

NCT ID: NCT06327048 Recruiting - Glioma Clinical Trials

Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment

Start date: March 6, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to form an interdisciplinary team to dynamically evaluate patient cognitive outcomes and develop an individualized cognitive training program for Chinese brain tumor patients

NCT ID: NCT06325527 Not yet recruiting - Alzheimer Disease Clinical Trials

Cognitive Impairment Cohort Study of the Elderly Population in YuGarden

Start date: April 1, 2024
Phase:
Study type: Observational

The goal of this prospective observational research with an 8-year follow-up is to study the cognitive changes in the elderly in YuGarden community, Shanghai, China. The main questions it aims to answer are: - incidence of cognitive impairment in community (converting to mild cognitive impairment or Alzheimer's disease) - to build a predictive model for the progression of cognitive impairment

NCT ID: NCT06325085 Recruiting - Clinical trials for Cognitive Impairment

Compensatory and Restorative Rehabilitation Techniques in Stroke

The
Start date: April 16, 2024
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial is to find the combined effects of restorative and compensatory cognitive rehabilitation techniques in mild cognitive impairment after stroke.

NCT ID: NCT06324227 Recruiting - Clinical trials for Mild Cognitive Impairment

Effects of Multimodal Music Intervention on Mild Cognitive Impairment Elderly

Start date: September 17, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about whether music therapy can ameliorate cognitive function, physical fitness and psychology in mild cognitive impairment and mild dementia population. The main questions it aims to answer are: 1. To build a model of multimodal music therapy. 2. To discuss the effect of twelve-week multimodal music therapy in ameliorating community-based elders with MCI and mild dementia. Main outcome variables: cognitive function (Montreal Cognitive Assessment Scale, trail making test, Saint Louis University Mental Status Examination). Secondary outcome variables: physical fitness (muscle strength, muscular endurance, flexibility, balance ability), depression.

NCT ID: NCT06321588 Recruiting - Dementia Clinical Trials

Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment

ADONIS
Start date: May 10, 2023
Phase:
Study type: Observational

The goal of this observational study is to investigate the frequency and the possible pathogenic role of neuronal synaptic antibodies (NSAb) in patients with cognitive impairment (CI). The main questions it aims to answer are: 1. the frequency and associated features of NSAb in patients with CI and the usefulness of a clinical score in improving autoimmune dementia (AID) diagnosis; 2. the clinical significance of NSAb in patients with CI not fulfilling the autoimmune encephalitis (AE) criteria and serum NSAb (NSAb-pos-CI); 3. the impact of blood-brain-barrier (BBB) dysfunction on their pathogenicity.

NCT ID: NCT06318390 Recruiting - Healthy Clinical Trials

The Impact of KETO5 XOGenius Beverage on Markers of Physiological and Neurocognitive Health

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The primary objectives of this application are to 1) investigate the effect of increased daily consumption of the Keto5 XOGenius beverage on outcomes associated with elevated risk for various neurocognitive and pathophysiological conditions/diseases. And 2) to investigate the effect of daily consumption of the Keto5 XOGenius beverage on the following variables: waist circumference, body weight, and body mass index (BMI).

NCT ID: NCT06318377 Recruiting - Healthy Clinical Trials

Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The overall research objective of this proposal is to determine the impact of increased daily peanut consumption on indices of neurocognitive and physiological health in BL individuals

NCT ID: NCT06316557 Not yet recruiting - Ischemic Stroke Clinical Trials

High-frequency rTMS on the Cerebellar to Improve Post-stroke Cognitive Impairment

HOPE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.

NCT ID: NCT06315972 Not yet recruiting - Schizophrenia Clinical Trials

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

OligoTreat
Start date: April 2024
Phase: Phase 2
Study type: Interventional

Schizophrenia (SZ) is a broad clinical entity characterized by different subjective symptoms,behavioural signs, and disease course. Research has pointed to numerous biological indicators tentatively associated with neurocognitive dysfunction, brain structural and neurochemical alterations. Cognitive deficits occur as early as the prodromal phase of the illness and significantly determine its outcome. Pathophysiologically, SZ is regarded as a disconnectome disorder in which frontal and temporal brain regions are functionally disconnected, which contributes substantially to the development of cognitive dysfunction. Impaired connectivity is related to synaptic (microconnectivity) and myelin (macroconnectivity) plasticity. With design-based stereology, a decreased number of oligodendrocytes (OLs) in the CA4 hippocampal subregion as the basis for disturbed myelination and impaired cognition, but also a decrease in the prefrontal cortex were observed. Animal studies demonstrated that clemastine enhances remyelination by increasing the differentiation of oligodendrocyte precursor cells (OPCs) and showed that aerobic exercise increases the rate of remyelination and proliferation of OPCs; this clinically meaningful effect of aerobic exercise is stronger in combination with clemastine. Furthermore, aerobic exercise improves everyday functioning, measured by the Global Assessment of Functioning (GAF) scale, and cognitive dysfunction in SZ and increases hippocampal volume, especially the volume in the hippocampal CA4 subregion. This regional volume change correlates negatively with global and cell-specific polygenic risk scores (PRSs), indicating that OPCs are involved in the genetic risk mechanisms and disturbed plasticity underlying SZ. In patients with multiple sclerosis, 90 days' administration of clemastine fumarate 10.72 mg/day, corresponding to clemastine 8 mg/day, significantly decreased the P100 latency delay of visual evoked potentials (VEPs) as a sign of myelin repair. In a bicentric, randomized, double-blind, controlled phase IIb clinical trial with a 2-arm parallel group design in patients with SZ, the study will compare the effects of aerobic exercise training plus clemastine vs. aerobic exercise training plus placebo over a period of 3 months on 1) everyday functioning and 2) working memory as primary outcomes.